SHAPING THE STANDARD OF CARE WITH TARGETED MEDICINE
The Best of Lung Dinner Symposium will take place on Friday October 30th, 2015 following The Best of Lung Cancer Summit.
Click here for more information.
Medical oncologists, pharmacists, nurses, and other oncology healthcare professionals who specialize in lung cancer.
After taking part in the program, participants will be able to:
- Describe the Canadian standards for molecular testing in NSCLC
- Understand the gaps in having lung cancer patients tested for biomarkers
- Discuss approaches for maximizing outcomes on the standard of care in the management of ALK positive NSCLC
Dr. Barbara Melosky, MD, FRCPC
Dr. Melosky is a Clinical Associate Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at the British Columbia Cancer Agency. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and a oncology fellowship at the University of British Columbia. She specializes in the fields of lung and gastrointestinal malignancies. She sits on the Executive Committee for NCIC and is the annual chair of the Canadian Lung Cancer Conference. She has a special interest in the side effects of cancer therapy.
Dr. Ming Tsao, MD, FRCPC
Dr. Tsao is a Clinician Scientist at The Princess Margaret and a Professor of Laboratory Medicine and Pathobiology at the University of Toronto. His specialty is Pathology that includes making diagnoses based on biopsies or tissues that have been removed by surgery. He is also Director of the Lung Cancer Translational Research Laboratory at PMH. His research laboratory is funded by the National Cancer Institute of Canada and the Canadian Institutes of Health Research, and he has published more than 100 peer-reviewed manuscripts in various biomedical journals.
Dr. Parneet Cheema, HBsc, M.D., MBiotech, FRCPC
Dr. Cheema is a Medical Oncologist at the Sunnybook Odette Cancer Centre with a focus in thoracic, gastrointestinal and skin malignancies. Dr. Cheema completed her undergraduate medical training at the University of Calgary, followed by Internal Medicine, and Medical Oncology training at the University of Toronto. Dr. Cheema also completed a Master’s degree in Biotechnology from the University of Toronto that focused on bringing scientific advances from bench to bedside. She has been principle investigator for clinical trials in the areas of melanoma and NSCLC including immunotherapies and targeted therapy.
Anne Marie Cerato
Anne Marie Cerato, OCT is a former educator who through her own experience with lung cancer has become a patient advocate and board member for Canada’s only lung cancer specific organization (Lung Cancer Canada). She is co-editor for CKN’s Young Adult section, a public speaker and a 5+ year lung cancer survivor.
Sponsored by Pfizer Oncology & EMD Serono
Member Comments. (0)
Please log in to add a comment.